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Abstract 
Objectives: To foster value-based pricing and coverage with evidence development in Germany, 
certain new diagnostic and treatment methods have been subject to a benefit assessment since 
2016 to determine their reimbursement. While this is a paradigm shift, the German approach is 
limited to some few specific technologies that request reimbursement. As physicians are 
encountered with this regulatory instrument, the aim of the study is to understand physician 
decision making regarding the adoption of new medical technologies and to identify physicians’ 
perspectives on the evidence base and the financing with additional reimbursement instruments. 
Methods: From April to August 2017 semi-structured interviews with chief and senior 
physicians on vascular surgery and cardiology in German inpatient care were conducted (n=23). 
The interviews were carried out by one researcher in one-to-one appointments or via telephone. 
Data was analysed inductively to identify factors and generate thematic categories using 
qualitative content analysis.  
Results: We identified 52 factors in eight categories influencing physicians in their adoption of 
new technologies. The evidence base of new technologies was criticised (e.g. the lack of 
available studies) while the knowledge of physicians varies concerning the regulation of market 
approval and innovation payments. They recommend utilisation of new technologies in certain 
specialist centres and facilitating observational studies.  
Conclusions: Physicians see the necessity of the new approach and support its aim. However, the 
design and implementation seems to be questionable from their medical perspective. The 
provision of summarised information on the benefit of technologies might be a possibility to 
assist physicians’decision making.  
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Introduction 
When new medical technologies enter the market, the time of adoption is a key point in patient 
care as evidence and experiences regarding its utilisation differ in their extent [1]. Many new 
technologies are capable of leading to better outcomes in patients’ treatment and diagnostic. 
However, there might be uncertainty and risks regarding the effectiveness of these technologies 
as at the time of market approval only little or no evidence is available [2, 3]. Thus, the adoption 
and utilisation of new technologies is necessary in order to gather knowledge and real-world 
evidence. This is especially the case for medical devices in the European Union (EU) where 
requirements to gain market approval are generally lower than, for instance, in the United States 
(US) [4].  
When focusing on new technologies that are used in inpatient care with the aim of maximising 
patient benefit and avoiding risks [5], the primary adopters are physicians. They assess treatment 
options and decide, sometimes within team decisions, whether to adopt a new technology or to 
use established alternatives. A variety of studies have investigated factors that influence 
physicians in their decision making. Several quantitative studies have evaluated the influence of 
hospital characteristics [6, 7], external factors (e.g. financing systems and reimbursement) [8, 9] 
and technology-related factors of particular technologies [10, 11]. Qualitative studies highlight 
that adoption decisions are based on financial and social pressures while evidence is often limited 
[12, 13]. Different dimensions to categorise factors influencing the decision making have been 
developed broadly differentiating between adopter specific, technology-related and external 
factors [14–18]. However, most of these studies use previously developed categories and fill the 
existing ones, which may undermine relevant aspects that do not fit into the used model.  
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Especially, the trade-off between the time of adoption and the evidence base is highly relevant for 
physicians with regard to technology adoption decisions, but also for health systems. In the light 
of limited resources and high health expenditures, from which a large share is spent on 
technologies, health care systems and payers are under pressure to control their expenditures [19]. 
Many countries, therefore, have introduced schemes to reimburse only those new technologies 
that have shown a benefit. The central idea is to link the value of a technology to its coverage 
decision and price setting [3]. However, due to the often low level of available evidence on new 
technologies’ effectiveness the approach of coverage with evidence development (CED) has 
emerged. The technology is covered from health insurers, while obligatory generating further 
post-market evidence. The approach was originally implemented for Medicare in the US [20] and 
has been adapted in France [21], Germany [22], Sweden and the Netherlands [23], just to name a 
few. While these CED approaches exhibit common elements (e.g. a clear legal foundation and a 
preference for high quality study designs), their specifics depend on the underlying health system 
of the countries. Differences exist with regard to the types of technologies being assessed (i.e. 
drugs, procedures or medical devices) [22]. Compared to other countries the German approach, 
introduced in 2016, is based on an early benefit assessment (§137h in combination with §137e 
Social Code Book V (SGB V)) that focuses on a particular group of medical devices. 
Furthermore, the approach has been linked to the concept of inpatient innovation payments (see 
the ‘Methods’ section for detailed information). It is a further step in the paradigm shift for the 
medical device industry, for patient care, and for inpatient physicians adopting these 
technologies.  
Since no international literature is available on this German health policy reform and its 
relevance in clinical practice, we aim to fill this gap. Based on this focus, the term ‘new 
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technologies’ includes medical devices and also diagnostic and treatment methods, but excludes 
pharmaceuticals.  
The aim of this study is to 
(1) depict the German CED scheme, in order to gain more in-depth insights into the decision 
making of physicians adopting new technologies, and  
(2) to explore physicians’ perspectives on the trade-off between evidence base and 
reimbursement of new technologies.  
Our research has been led by two research questions: 
I. How do physicians describe their decision criteria whether to adopt a new technology in 
patient care? 
II. What experiences and constructive remarks do physicians have on the evidence base and 
the financing of new technologies?  
Methods 
Brief overview on the German CED reform in 2016 
Because this study’s aim and consequently the interviews’ questionnaire’s development was 
based on the German health policy reform on CED the approach will be introduced in this 
chapter. It clarifies why the reform especially affects physicians, which is e.g. the responsibility 
to deliver further information on a medical device or its exclusion from reimbursement. 
Before 2016, approved new technologies generally could be used in German inpatient care 
without a prior external assessment (§137c SGB V). In 2012, CED was first introduced for 
diagnostic and therapeutic methods (§137e SGB V) for which the German Federal Joint 
Committee (G-BA) have passed a directive for the conduction of clinical trials to gather 
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additional data on effectiveness and safety [22]. The reform of 2016 focusses on new diagnostic 
and therapeutic methods whose technical application is based essentially on a medical device of 
high risk class (in short: ‘high-risk medical device’). ‘High-risk medical devices’ according to the 
SGB V are (1) medical devices of risk class IIb or III in line with the Directive 93/42/EEC or 
active implantable medical devices in line with the Directive 90/385/EEC
1
 whose (2) application 
possess a highly invasive character. ‘New diagnostic and therapeutic methods’ thereby are 
defined as medical procedures with a new theoretical and scientific concept. The term ‘method’ 
includes procedures in terms of a ‘physician-led treatment concept’ characterised by a certain 
degree of complexity. It is thus distinct from other medical devices, such as medical instruments 
or appliances, that are used for one-step procedures [24]. The underlying new theoretical and 
scientific concept has to differentiate the method from others [24]; i.e., according to §137h SGB 
V, the new method’s mode of action or its field of application needs to differ substantially from 
systematic approaches already introduced in inpatient care. One example for a method that has 
been considered for assessment so far is the Coronary Lithoplasty for the treatment of Coronary 
Heart Disease (CHD). It is set apart from, e.g., the Rotablation, that is utilised in the treatment of 
CHD using another mode of action for coronary plaque ablation [25].  
Figure 1 provides a schematic overview of the new approach [26]. Starting point of an early 
benefit assessment is a first application on innovation payments for new health technologies, so 
called ‘New Diagnostic and Treatment Methods’ (‘NUB’). Innovation payments are separate 
from the DRG system  that involve additional funding (i.e., are paid on a fee-for-service basis) 
and are negotiated locally [27, 28]. The benefit assessment of a method leads to one of the 
following results: 1) sufficient proof of benefit, 2) no sufficient proof but potential of benefit, 3) 
                                                 
1
 As from 25 May 2017 the new Medical Device Regulation (MDR) came into force. Regulation (EU) 2017/745 will replace the 
directives concerning medical devices and active implantable devices after a transitional period of 3 years. 
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no sufficient proof of benefit. According to the Institute for Quality and Efficiency in Health Care 
(IQWiG), ‘benefit’ is defined as valid positive effects of methods concerning patient-related 
endpoints (e.g. mortality, morbidity or patients’ quality of life) compared to placebo or 
comparator interventions [29].   
[Figure 1 about here.] 
Design and participants 
As the complexity of adoption processes is well known [17], we applied qualitative content 
analysis to adequately consider this organisational phenomenon [30]. The study was approved by 
the ethical committee of the Technische Universität Berlin via fast track procedure. We collected 
data based on in-depth semi-structured interviews, enabling us to ask context-driven additional 
questions [31]. The questionnaire covered the following subject areas: (I) Factors influencing 
physicians in their decision to adopt new technologies, (IIa) physicians’ assessment of the 
evidence base and (IIb) physicians’ assessment of the concept of innovation payments in clinical 
practice. With the aim of testing comprehensibility and appropriateness of the questions, a pilot 
test was conducted with two physicians [32]. The interviews of the pilot study were not part of 
the analysis. 
In order to identify medical disciplines encompassing a variety of new and higher priced 
technologies compared to standard technologies, the German lists of requested innovation 
payments (2011-2015) were screened. As a result we conducted all interviews in the disciplines 
of vascular surgery and cardiology or other designation also carrying out interventions in these 
fields, e.g. internal medicine. We identified all relevant inpatient hospitals in the city of Berlin 
and the federal state of Brandenburg limiting the regional area for the following reasons: (1) 
Keeping the area of investigation small sized enables us to interview physicians by the same 
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researcher preventing bias of different researchers [33]. (2) Berlin as a populous city with a high 
hospital density and Brandenburg depicting the suburban and also rural region give a variety in 
hospitals’ sizes and provider types [34, 35]. The recruitment process was realised from March to 
July 2017 contacting n = 173 physicians. The overall response rate was about 20% (n = 33). 
However, ten physicians rejected the invitation due to a lack of time or interest.   
The semi-structured interviews were carried out in one-to-one appointments or via telephone 
from April to August 2017, were audio-taped and lasted between eleven and 33 minutes. After 
conducting 23 interviews, no fundamentally new information or arguments emerged. As this 
indicates the point of saturation was reached [36], no further physicians were recruited. 
Data editing and analysis  
The recordings were transcribed verbatim by an external office and the transcripts were 
anonymised by two researchers. With the aim to prevent information processing bias and to 
ensure a systematic analysis of qualitative data, we used the analytical software tool Atlas.ti 
(version 8.0) for coding [37]. All relevant text passages were coded separately by two researchers 
while directly deriving code titles from the text data [38]. Two rounds of analysis were 
conducted: A first set of codes was developed based on a discussion with the option of adding or 
amending codes for further analysis. With the aim to harmonise the analysis, we compared the 
final results after the second round to reach consensus [39]. In case of disagreement, a neutral 
researcher was consulted and codes were discussed. For answering the first research question all 
codes representing factors that influence physicians in their decision making were pooled in 
thematic categories using the bottom-up-approach [40]. To answer the second research question 
codes were systematically ordered.  
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Results 
The data set consists of 23 in-depth semi-structured interviews with chief and senior physicians 
on vascular surgery and cardiology in inpatient care. The interviewed physicians have practiced 
in mean 24.7 years and 8.6 years in their current position. The departments have a mean of 50.5 
beds. Table 1 gives an overview of the physicians’ characteristics, the departments and hospitals. 
[Table 1 about here.] 
Factors influencing physicians’ decision on the adoption of new technologies 
In the interviews, a total of 52 individual factors were identified that physicians described as an 
influence in their decision to adopt a new technology. We grouped these factors into eight 
thematic categories, representing influences through (1) the technology, (2) the evidence base, (3) 
the state of medical care, (4) the manufacturer, (5) regulation, (6) the hospital, including its 
institutional characteristics and its strategy, (7) the individual, and (8) the patient. Figure 2 
displays these categories including the influencing factors. 
[Figure 2 about here.] 
Technology-related factors include the handling of a medical device experienced by physicians, 
its durability and extent of improvement, and if it reduced the invasiveness of a treatment. Due to 
the diversity of technologies, a single comparison of an individual characteristic is not possible, 
forcing physicians to make an overall assessment considering a variety of aspects. Physicians 
also assess the evidence base when deciding whether to adopt a technology. They are aware of a 
low evidence base of medical devices after their market authorisation, in particular in the EU. 
However, some physicians view this as an opportunity to adopt a technology carefully in a 
hospital setting. Others reported that this might nevertheless lead to an excessive proliferation of 
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new technologies. They criticised that available studies are often based on a very small patient 
cohort and are biased with regard to manufacturer interests.  
Furthermore, physicians’ decision to use new technologies includes the state of medical care. 
Interviewees value the level of care in their discipline as excellent with regard to the quality and 
availability of options. Thus, they set high standards for new technologies to compete against 
that. On the contrary, if few or no alternatives exist in an indication, such as in the case of rare 
diseases, physicians are willing to utilise certain new technologies despite lacking evidence. They 
cited guidelines as an important point of reference. 
Manufacturer-related factors are mentioned as a further factor influencing physicians in their 
decision to adopt new technologies. They described the influence of manufacturers’ sales 
activities, ranging from no interaction to using interactions as basically only source of 
information and criticised the focus on marketing activities. Furthermore, physicians consider the 
service provided by the manufacturers in their decision making. Another factor mentioned, was 
the manufacturer price and the cost-benefit-ratio, i. e. the manufacturer’s pricing strategy of a 
technology in relation to the expected benefits. They observe, that prices decrease after initial 
market launch; some report to wait until prices declined. 
In the context of regulation, relations between different factors of adoption play a significant 
role: reimbursement decisions and price developments are relevant in physicians’ decision 
making whether to adopt new technologies. Some physicians expressed to be able to utilise a 
technology even if they have to cross-finance it from other DRGs. 
Regarding hospital-related factors influencing the adoption, physicians distinguish between 
characteristics of the institution, such as the size and the type of provider, and strategic decision 
making of the hospitals. Interviewed physicians of non-university hospitals mentioned, that 
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university hospitals and specialist centres might have more possibilities of refinancing and thus 
should adopt new technologies first. They also reported to not have sufficient patient numbers in 
a certain indication to utilise new technologies. Strategic aspects of hospitals include internal 
processes regarding central purchasing, logistical efforts and coordination with administrative 
colleagues. Also, strategic hospital decisions such as to increase patient numbers and quality in 
patient care play a role in physicians’ decisions whether to adopt new technologies as also 
reputation and patient satisfaction. Many physicians mentioned that they do not feel under 
pressure to be the first to adopt a technology. Instead, they would wait for other clinicians to 
utilise the technology first in order to adopt it at a later stage when more experiences have been 
acquired.  
Regarding individual-related factors, physicians report their interest in something new and 
extraordinary as one driver to utilise new technologies, which is closely related to their 
personality. However, career and urge to publish articles constitutes a motivation, which the 
physicians assessed as a dominating incentive at times. Being familiar with a product can even 
set a certain barrier to not use new technologies.  
Regarding the patient-related factors that affect the decision to adopt new technologies 
physicians mention patients’ overall health and the compatibility of a technology with individual 
patients. While some physicians said they utilised new technologies primarily in young patients, 
others reported the opposite. Besides, some physicians are also willing to consider patient 
preferences for a certain technology, even in the context of implantable devices, while others do 
not. A selection of physicians’ statements on the determinants regarding the adoption decision of 
new technologies are listed in Table 2. 
[Table 2 about here.] 
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Physicians’ experiences and remarks regarding evidence base and financing of new 
technologies 
With regard to the second research question physicians overall expressed a trade-off between 
early adoption and the possibility to utilise innovative technologies, in particular in the case of 
new technologies without treatment alternatives. They criticised that the evidence base at point of 
market entry is scarce. Therefore, they sometimes prefer to wait for additional evidence. Many 
physicians complained, that some new technologies are financed too early by innovation 
payments. They additionally reported that the process of requesting and receiving an innovation 
payment is too complicated and inflexible. Table 3 gives an overview of the physicians’ 
experiences and remarks. Statements on the evidence base at the time of adoption were divided 
into comments regarding market authorisation, utilisation, and study situation. Physicians’ 
experiences and expectations about innovation payments consider issues with regard to the 
technology, the process of requesting and negotiating additional payments as well as the effects 
of this financing system. 
[Table 3 about here.] 
Discussion 
This study gives detailed information on factors determining the adoption of new technologies 
from clinicians’ point of view. The lack of evidence of individual values and attitudes of local 
innovators was previously highlighted by Varabyova [18]. Additionally, Hatz and colleagues 
conclude in their analysis of adoption decisions that the behaviour of physicians differs according 
to the length of time a cardiovascular medical device has been on the market. They thus 
differentiate between ‘new’ and ‘old’ medical technologies [17]. We contribute to the research on 
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the adoption of new technologies by picking up these differences and the identified research lacks 
and additionally investigated the role of innovation payments in combination with the 
introduction of a new regulatory approach for high-risk medical devices in Germany.  
Our in-depth analysis of physicians’ decision making whether to adopt new technologies 
generates eight thematic categories relevant for their utilisation. The study results show similar 
categories of influencing factors in German inpatient care as defined in previous literature [14–
18]. The category regulation refers to previously defined structural, contextual and environmental 
factors, depending on the wording [14–18]. Organisational factors known from the literature [14, 
16–18] are presented through hospital-related factors split into institutional and strategic factors. 
A particularity in health care is the structure of demand, as physicians use technologies in patient 
care, but actually the patient is the end user. Thus, we decided to split adopter-specific factors 
into (a) the individual category including factors of the physicians themselves and (b) the patient 
category covering patient-relevant adoption factors. Lastly, our results typically comprise 
technology-related factors.  
However, new thematic categories evolved. Further categories have to be defined supplementing 
the existing literature-based dimensions. Firstly, the state of medical care plays an important role 
in adopting decisions, i.e. the availability of alternative treatments, the existence of different 
technology generations, the availability of a follow-up treatment for certain technologies, etc. 
Most studies, do not consider these factors. The same holds true for the activities of the 
manufacturer, which have been described, but rarely occur in studies examining physicians’ 
adoption behaviour. Hatz and colleagues could show for the group of ‘new’ technologies that a 
perceived support of the manufacturer is associated with a higher probability of adoption [17]. 
Our results show that physicians expect a high service availability while they take a critical view 
on studies with regard to possible influences of manufacturers. High service availability might 
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improve device-operator interactions as it generates learning curve effects by gaining experiences 
within the utilisation of technologies. Learning curve effects might affect the technologies’ 
effectiveness [41], as shown by Varabyova et al. for endovascular aneurysm repair (EVAR), a 
minimally invasive treatment method for abdominal aortic aneurysms, emphasising the need of 
training with medical devices [42]. Additionally, physicians discuss the available evidence 
extensively. Hatz et al. did not identify perceived medical evidence as a major driver of adoption. 
Our results show that the evidence base, depending on the availability of treatment alternatives, is 
a factor influencing adoption decisions. Interviewed physicians assess studies and their evidence 
base on their own. However, there are also statements that the manufacturer serves as the basis 
for decision making. As the evidence base did not fit properly into either of the defined 
categories, we established an extra category. Indeed, physicians consider this aspect as an 
important issue to influence their decision.. Our results indicate that physicians experience the 
evidence base at the time of market entry usually to be scarce. In particular, the interviewed 
physicians criticise a lack of studies overall, a small number of patients in approval studies and a 
supposed influence of manufacturers in studies. Furthermore, they noted a lack of studies 
investigating the effectiveness of  technologies compared to their alternatives, highlighting that 
such studies are not required for medical devices in the EU. They view the additional benefit as a 
relevant indicator, since in their experiences many technologies had some minor improvements 
opposed to several complications and the overall uncertainty. Regarding financing of new 
technologies, many of the interviewed physicians have the power within the hospital to choose 
the product and manufacturer they prefer, even if it is more expensive than the calculated costs in 
the reimbursed rates. Nonetheless, physicians feel a personal responsibility to support the 
economic wellbeing of the hospital or the goal of breaking even. Therefore, the clinicians try to 
 15 
 
act within the scope of DRGs. This supports the notion that the diffusion of new technologies is 
steered by their reimbursement.  
Due to scarce evidence and the requirement of additional reimbursement, the physicians overall 
support the aim and objectives of the health policy reform. However, the design of the approach 
and its implementation is criticised. With regard to medical decision making based on evidence 
of effectiveness, this regulatory instrument will fall short. Additional evidence may be gathered 
only for a small group of technologies with the following prerequisites: (i) hospitals’ first request 
of innovation payment, (ii) defined as ‘high-risk medical device’, (iii) underlying ‘new 
theoretical and scientific concept’, (iv) status ‘potential’. Many technologies do not fall under this 
approach as it is currently designed (e.g. high-risk technologies without requests of innovation 
payments) 
Although this study allows a unique insight into physicians’ perspectives using the qualitative 
approach limitations need to be mentioned [43]: Besides researchers’ individual conclusions in 
analysis, study results might not be representative for all physicians [44, 45]. Additionally, using 
telephone interviews implies disadvantages compared to an appointment in person (e.g. a lack of 
interaction between interviewer and participant) [46]. However, conducting telephone interviews 
offered some assets (e.g. high response rate, low costs) [47]. Furthermore, we interviewed chief 
and senior physicians only, professionals in a certain hierarchical and thus experience level. Since 
years in practice of physicians were found to be negatively associated with the adoption of new 
technologies [48, 49], clinicians in other positions also should be considered in further analysis. 
Overall, as the analysis is based on 23 interviews used to identify a wide range of factors 
influencing physicians’ adopting decisions, further quantitative studies are necessary to 
investigate factors according to their relevance in adopting decisions and their relations. 
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Conclusions 
This study offers an in-depth understanding of factors influencing the decision making of 
clinicians to adopt new technologies. We identified 52 factors that are allocated in eight thematic 
categories and depict the overall trade-off that physicians have to handle in their adoption 
decisions.All interviewed physicians supported the general notion of conducting benefit 
assessments and, if necessary, generating additional evidence. However, they criticize the design 
and implementation of the German approach.  They appreciate improvements in receiving 
summarised information. Therefore, a further step and a challenge for policy makers and payers 
could be, to bring together country specific evidence on the effectiveness of new technologies on 
European level to build up a transnational overarching database. A central provision of 
summarised evidence might assist physicians in their decision whether to use new technologies. 
Overall, the results of the 23 interviews analysed based on qualitative content analysis should be 
verified via quantitative studies in a further step to investigate factors according to their relevance 
in adopting decisions and their relations in more detail. 
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